Netherlands-based Qiagen has announced the launch of its QIAstat-Dx with SARS-CoV-2 Respiratory Panel for syndromic testing in Japan.
The test is expected to be available during the middle of this year, subject to decisions related to reimbursement levels. The planned launch follows the recent in vitro diagnostic approval.
When used with the respiratory panel, the QIAstat-Dx allows for the identification of more than 20 pathogens in a single patient sample.
Qiagen senior vice-president and molecular diagnostics business area head Jean-Pascal Viola said: “We are pleased to announce the upcoming availability of our QIAstat-Dx SARS-CoV-2 Respiratory Panel in Japan which enhances our commitment to improving healthcare around the world.
“QIAstat-Dx enables easy operation with less labour compared to standard individual PCR assays for each pathogen and provides powerful support for medical workers in respiratory medicine, paediatrics and emergency medicine.”
Intended for laboratory use, the system utilises disposable cartridges that contain all reagents and feature built-in sample processing.
QIAstat-Dx uses multiplex real-time polymerase chain reactions to identify and distinguish various pathogens.
The first group of panels are intended for identifying respiratory or gastrointestinal pathogens, or for differentiating between infections caused by meningitis and encephalitis.
QIAstat-Dx comes in two different formats of which the standard version combines up to four analytical modules to create a single, integrated system.
The QIAstat-Dx Rise high-capacity version utilises eight analytical modules and has the capability to perform comprehensive testing for up to 160 tests a day.
QIAstat-Dx is claimed to be the only syndromic testing system that offers access to amplification curves and Ct values, helping in making informed decisions for patients.